News

New tacrine hopes for Alzheimer patients in US

BMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6935.999a (Published 16 April 1994) Cite this as: BMJ 1994;308:999
  1. F B Charatan

    A 30 week study reported in the 6 April issue of JAMA of 663 patients at 33 outpatient centres throughout the US has opened a new chapter in the evaluation of tacrine (tetrahydroaminoacridine; Cognex). The study was led by the manufacturer of the drug, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company. Last September the Food and Drug Administration (FDA) approved the use of tacrine, a long acting anticholinesterase, in Alzheimer's disease.

    The study was to determine the effects of high dose (up to 160 mg/day) tacrine in patients with a probable diagnosis of Alzheimer's disease with the presence of symptoms …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe